– USA, MA – Harvard Bioscience, Inc. (Nasdaq: HBIO) announced the appointment of Steve DeNelsky to its Board of Directors, effective September 5, 2025.
Steve DeNelsky will also join the Nominating and Governance Committee.
About Stephen DeNelsky
Steve DeNelsky possesses 30 years of experience in the research, analysis, and valuation of public and private equities in the healthcare industry. He serves as Managing Director at Oaktree Capital Management and has held senior roles at Marathon Asset Management and Life Sciences Alternative Funding. He has worked across all major sub-sectors of healthcare, including life sciences, pharmaceuticals, devices, and services.
Steve DeNelsky also brings strong board experience and currently serves on the board of Visioncare Inc. and previously served on the boards of Integrated Diagnostics and AMICAS, Inc.
Steve DeNelsky received a B.A. in Economics from the American University and an M.B.A. from the University of Maryland.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies, products, and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production, and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology, and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more: https://www.harvardbioscience.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.